A5021676511- Metal complexes synthesis and properties
- Bladder and Urothelial Cancer Treatments
- Ferrocene Chemistry and Applications
- Ferroptosis and cancer prognosis
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- Advanced biosensing and bioanalysis techniques
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
University of Colorado Anschutz Medical Campus
2019-2024
University of Colorado Denver
2019-2020
Erasmus University Rotterdam
2011
Amsterdam UMC Location Vrije Universiteit Amsterdam
2007
There is an unmet need to improve the efficacy of platinum-based cancer chemotherapy, which used in primary and metastatic settings many types. In bladder cancer, chemotherapy leads better outcomes a subset patients when neoadjuvant setting or combination with immunotherapy for advanced disease. Despite such promising results, extending benefits platinum drugs greater number highly desirable. Using multiomic assessment cisplatin-responsive -resistant human cell lines whole-genome CRISPR...
<p>Supplementary Figures and Supplementary Table legends.</p>
<p>Supplementary Figures and Supplementary Table legends.</p>
<div>Abstract<p>There is an unmet need to improve the efficacy of platinum-based cancer chemotherapy, which used in primary and metastatic settings many types. In bladder cancer, chemotherapy leads better outcomes a subset patients when neoadjuvant setting or combination with immunotherapy for advanced disease. Despite such promising results, extending benefits platinum drugs greater number highly desirable. Using multiomic assessment cisplatin-responsive -resistant human cell...
<div>Abstract<p>There is an unmet need to improve the efficacy of platinum-based cancer chemotherapy, which used in primary and metastatic settings many types. In bladder cancer, chemotherapy leads better outcomes a subset patients when neoadjuvant setting or combination with immunotherapy for advanced disease. Despite such promising results, extending benefits platinum drugs greater number highly desirable. Using multiomic assessment cisplatin-responsive -resistant human cell...
ABSTRACT There is an unmet need to improve efficacy of platinum-based cancer chemotherapy. Using multi-omic assessment cisplatin-responsive and -resistant human bladder cell lines whole-genome CRISPR screens, we identified Puromycin-Sensitive Aminopeptidase, NPEPPS, as a novel driver cisplatin resistance. NPEPPS depletion sensitizes resistant cells in vitro vivo . Conversely, overexpression sensitive increased We show that affects treatment response by regulating intracellular...
Gemcitabine and cisplatin (GC) combination neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for treating muscle-invasive bladder cancer (MIBC). Approximately 25% patients experience complete pathologic response (pT0), while remaining ~75% have residual disease poorer prognosis. Therefore, defining mechanisms that enable cells to survive NAC will allow us I) identify predictive biomarkers improve MIBC patient stratification NAC, II) define novel...
Abstract Gemcitabine and cisplatin (GC) combination neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for treating muscle-invasive bladder cancer (MIBC). Approximately 25% patients experience complete pathologic response (pT0), while remaining ~75% have residual disease poorer prognosis. Therefore, defining mechanisms that enable cells to survive NAC will allow us I) identify predictive biomarkers improve MIBC patient stratification NAC, II) define...
Abstract Neoadjuvant platinum-based chemotherapy (NAC) followed by radical cystectomy is the preferred first-line option for treating patients diagnosed with muscle-invasive bladder cancer (MIBC). One of two most commonly utilized regimens MIBC consists combination therapy gemcitabine and cisplatin (GC). Importantly, cisplatin-based leads to complete response (pT0) in approximately 25% patients, while remaining 75% are left residual disease. For presence disease at associated significantly...
Abstract Gemcitabine and cisplatin (GC) combination neoadjuvant chemotherapy (NAC) is standard of care for patients with muscle-invasive bladder cancer (MIBC). This preferred due to its favorable toxicity profile. Approximately 25% NAC treated will experience complete pathological response (pT0) at time radical cystectomy (RC). NAC-treated residual disease RC have poorer prognosis compared those who achieved pT0. Here we systematically defined the in vitro functional determinants resistance...